AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes.
[More]
The newest public health threat in Africa, scientists have found, is coming from a previously unknown source: the banded mongoose.
[More]
The newest public health threat in developing countries may not be a cinematic-quality emerging disease but actually a disease from animals that was identified more than 100 years ago.
[More]
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
[More]
Using regional anesthesia instead of general anesthesia in patients with sleep apnea undergoing total joint replacement decreases major complications by 17%, according to a study published online, ahead of print, in the journal Regional Anesthesia and Pain Medicine.
[More]
A highly underutilized anesthesia technique called neuraxial anesthesia, also known as spinal or epidural anesthesia, improves outcomes in patients undergoing hip or knee replacement, according to a new study by researchers at Hospital for Special Surgery.
[More]
Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.
[More]
DaVita, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today announced that DaVita Hospital Services, the company's inpatient kidney care services, has received Ambulatory Health Care Accreditation from The Joint Commission.
[More]
ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.
[More]
Good news for anyone needing a transplant; a new Mayo Clinic survey shows that the public's support for both living and deceased organ donation is increasing.
[More]
Bioengineered rat kidneys developed by Massachusetts General Hospital investigators successfully produced urine both in a laboratory apparatus and after being transplanted into living animals.
[More]
Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease.
[More]
Saline is just salty water, whereas colloids are solutions that have large molecules in them. In this case, the molecules are starch. The idea is that because these molecules are big they don’t leak out of the circulation as much.
[More]
Scientists all over the world are on a quest for an antidote since the first patient died from the new coronavirus in summer 2012. Infection Researchers from the German Primate Center have now identified enzymes that activate the virus for infection.
[More]
Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA.
[More]
PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia.
[More]
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia.
[More]
Starch-based intravenous (IV) fluids used by the NHS to treat seriously ill patients are causing unnecessary deaths, according to a new Cochrane systematic review by researchers at the London School of Hygiene & Tropical Medicine.
[More]
CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human].
[More]
In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA.
[More]